Home > Haematology > EHA 2021 > Lymphoma > The journey ahead for CAR T-cell therapy in r/r follicular lymphoma

The journey ahead for CAR T-cell therapy in r/r follicular lymphoma

Presented By
Dr Bastian von Tresckow, University Hospital Essen, Germany
Conference
EHA 2021
Trial
ZUMA-5; ELARA
Preliminary results from 3 independent phase 2 trials are promising for CAR T-cell therapies in patients with relapsed or refractory (r/r) follicular lymphoma. Follicular lymphoma has a generally good prognosis, but approximately 20% of patients experience disease relapse within 2 years of initial first-line chemo-immunotherapy and survival rates are as poor as 50% in these patients [1]. With each line of therapy, survival rates significantly decline [2]. CAR T-cell therapy is being developed as an option for early treatment failures as well as multiple relapses, as discussed by Dr Bastian von Tresckow (University Hospital Essen, Germany) [1]. Long-term data from a single-centre, phase 2a study (NCT02650999) with CAR T-cell therapy with pembrolinzumab (targeting cell surface receptor P...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on